Form 4: Outlook Therapeutics Director and 10% Owner Boosts Stake in Public Offering

Ghiath M. Sukhtian and GMS Ventures & Investments, a director and 10% owner of Outlook Therapeutics, Inc., acquired over 4.2 million shares of common stock and 8.5 million warrants in a recent underwritten public offering at $1.40 per unit.

Summary

• Ghiath M. Sukhtian, a director and 10% owner of Outlook Therapeutics, Inc. (OTLK), along with GMS Ventures & Investments, acquired common stock and warrants in an underwritten public offering.
• The transaction, dated May 27, 2025, involved the acquisition of 4,285,714 shares of common stock.
• For each share of common stock acquired, accompanying warrants to purchase two shares of common stock were also acquired, totaling 8,571,428 warrants.
• The purchase price for each share and accompanying warrant was $1.40.
• Following this transaction, the reporting persons beneficially own 13,552,359 shares of common stock and 8,571,428 warrants.
• The warrants have an exercise price of $1.40, became exercisable on May 27, 2025, and expire on May 27, 2030.
• GMS Ventures & Investments holds these securities of record, and Ghiath Sukhtian, holding a controlling interest in GMS Ventures, is deemed to have voting and investment power, and is considered a director by deputization.

Sentiment

Score: 8

Explanation: The significant acquisition of shares and warrants by a director and 10% owner in a public offering demonstrates strong insider confidence and provides capital to the company, which is a positive signal for investors.

Positives

• A significant acquisition of shares and warrants by a director and 10% owner signals strong insider confidence in Outlook Therapeutics' future prospects.
• The underwritten public offering provides capital to the company, which can be used for operations, research, or other strategic initiatives.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transaction involves Ghiath M. Sukhtian and GMS Ventures & Investments, who are identified as a director and 10% owner of Outlook Therapeutics, Inc., making this a related party transaction.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it indicates strong insider confidence, potentially boosting investor sentiment.
• Company: The public offering provides additional capital, which can support ongoing operations, development, and strategic initiatives.

Key Dates

Recommendation

Keywords

Outlook Therapeutics, OTLK, SEC Form 4, Insider Trading, Beneficial Ownership, Public Offering, Common Stock, Warrants, Ghiath M. Sukhtian, GMS Ventures & Investments, Director, 10% Owner, Equity Acquisition